HOUSEAT2NDREADING

Private Member's Bill

Senate

45th Parliament · Session 1

Bill S-201: An Act respecting a national framework on sickle cell disease

National Framework on Sickle Cell Disease Act

Introduced

May 28, 2025

Current Stage

HouseAt2ndReading

Last Updated

April 17, 2026

Community Support

Community Vote

0% Support

0 votes

Support

Undecided/Abstain

Oppose

Cast Your Vote

Your vote helps inform others

Engagement

Votes

Comments

Follows

Parliamentary Votes

Statements

Bill S-201

Fri Apr 17 2026

An Act respecting a national framework on sickle cell disease

Impact Rating

2/5

Short Summary

Mandates a national plan for Sickle Cell Disease, focusing on newborn screening, better disability benefits, and a diverse blood donor supply.

Sickle Cell Disease

Healthcare

Disability Benefits

Blood Donation

Newborn Screening

Detailed Analysis

This bill forces the Federal Minister of Health to create a national strategy for tackling Sickle Cell Disease. It aims to standardize how the disease is diagnosed and treated across Canada, ensuring that where you live doesn't determine the quality of care you receive. Specifically, the government must look into adding Sickle Cell to disability benefit lists, creating a national patient registry, and ensuring newborn babies are screened for the condition.

Why does this bill exist?

Origin (Public Outcry/Event)

Sickle Cell advocates have long argued that the disease is underfunded and misunderstood compared to other genetic conditions, often due to it primarily affecting Black and racialized communities.

Key Points

Mandates the creation of a 'National Framework' within one year to standardize care.
Requires an analysis of giving patients and caregivers a specific tax credit.
Seeks to ensure Sickle Cell Disease is explicitly eligible for existing federal disability benefits.
Proposes universal screening for all newborns to catch the disease early.
Focuses on diversifying the blood supply, which is critical for safe transfusions for Sickle Cell patients.
Establishes a national research network and data registry to track the disease.

Impact By Group

Sickle Cell Patients

(Rights Expanded)

May eventually qualify for disability payments and tax credits that are currently difficult to access.

Healthcare Professionals

(Neutral)

Will receive new training guidelines and standardized protocols for treating pain crises.

Parents of Newborns

(Easier)

Automatic screening means earlier diagnosis without having to fight for a test.

Provincial Impact

High (Requires Provincial Action/Funding) Interaction

Since hospitals and doctors are provincial, the Federal Minister must convince provinces to adopt these new standards and share data for the registry.

Benefits & Pros

Could provide financial relief to families by reviewing tax credits and disability eligibility.

Standardizes care, preventing 'postal code lotteries' where treatment varies by province.

Increases safety of blood transfusions by promoting donor diversity.

Early detection via universal screening saves lives and reduces long-term complications.

Beneficiaries

Patients with Sickle Cell Disease

Black and Caribbean Canadian communities

Medical Researchers

Risks & Cons

As a 'Framework' bill, it creates a plan but does not immediately spend money on treatment or benefits.

Healthcare is primarily a provincial responsibility, so the federal government cannot force provinces to adopt every standard.

The timeline for actual change is slow; the first report on effectiveness isn't due for four years total.

Affected Groups

None directly (Taxpayers indirectly if future spending increases)

Before & After

Currently, a patient in one province might get comprehensive care while a patient in another gets none, and many struggle to qualify for disability payments. Under this bill, national standards would define proper care, and federal benefits would be adjusted to explicitly include Sickle Cell patients.

Real World Scenario

Currently: A parent of a child with Sickle Cell struggles to pay for meds and is denied the Disability Tax Credit because the condition is 'episodic.' Under this Bill: The government would revise the tax credit rules to specifically recognize the severity of Sickle Cell, allowing the parent to qualify.

Frequently Asked Questions

Will this give me money for my medication?

Does this make Sickle Cell a disability?

House of Commons

First reading

Completed on December 11, 2025

Second reading

In Progress

Consideration in committee

Not yet started

Report stage

Not yet started

Third reading

Not yet started

Senate

First reading

Completed on May 28, 2025

Second reading

Completed on June 12, 2025

Consideration in committee

Completed on October 23, 2025

Third reading

Completed on November 18, 2025

Abuse Potential

The abuse potential is low regarding government overreach. The primary risk is 'performative legislation'—where the government spends money on reports and committees (the framework) to appear active, without actually funding the recommended tax credits or drug coverage later. The bill mandates 'analysis' of benefits, not the benefits themselves.

Financial Impact

Administrative costs for consultations and report writing (approx. $1-2 million). Future costs could be significant if the government actually implements the recommended tax credits or drug coverage.

Implementation Risk

The main risk is lack of provincial buy-in. If provinces refuse to share patient data for the registry or adopt the training standards, the 'National Framework' becomes a paper tiger.

Broad Economic Impact

Indirect

Everyday Life

Minimal impact

Admin Burden

No changes to daily routine

Timeline

Phased in over 3 years

Bill Text Versions

2 Versions

View different versions of the bill text or compare changes between versions

Select Version

Summary

This enactment provides for the development of a national framework to support Canadians with sickle cell disease (also known as sickle cell anemia or drepanocytosis), their families and their caregivers.

Full Text

Short Title Short title 1 This Act may be cited as the National Framework on Sickle Cell Disease Act . National Framework on Sickle Cell Disease National framework 2 (1) The Minister of Health must develop a national framework on sickle cell disease. Content (2) The national framework must (a) include measures to address the training, education and diagnostic and treatment tool needs of health care professionals relating to sickle cell disease ; (b) provide for the creation of a national research network to advance research, improve data collection and establish a national registry on sickle cell disease; (c) set evidence-based national standards for the diagnosis and treatment of sickle cell disease; (d) include measures to institute universal neonatal screening, postnatal diagnosis when necessary and the provision of results for affected individuals and organizations; (e) include measures to support public awareness campaigns on sickle cell disease and blood donation; (f) provide for measures to promote and support blood donation by every segment of the population and the creation of a diverse blood supply that allows for safe transfusions; (g) include an analysis respecting the implementation of a tax credit for individuals with sickle cell disease and their caregivers; (h) ensure the inclusion of sickle cell disease in the eligibility criteria for existing disability benefits; and (i) contain an analysis of the potential inclusion of treatments essential to sickle cell disease care in public drug insurance plans. Consultations (3) For the purpose of developing the national framework, the Minister of Health must consult with (a) any minister who, in the Minister’s opinion, has relevant responsibilities; (b) representatives of the provincial and territorial governments; (c) relevant stakeholders, including self-advocates, caregivers, support persons, service providers, representatives of the medical and research communities, and organizations that the Minister considers to have relevant expertise and experience relating to sickle cell disease; and (d) any other person or entity that the Minister considers appropriate. Reports to Parliament Tabling of national framework 3 (1) Within one year after the day on which this Act comes into force, the Minister of Health must prepare a report setting out the national framework on sickle cell disease and cause it to be tabled in each House of Parliament on any of the first 15 days on which that House is sitting after the report is completed. Publication (2) The Minister must publish the report on the Department of Health website within 10 days after the day on which the report is tabled in Parliament. Report 4 Within three years after the day on which the report referred to in section 3 is tabled in Parliament, the Minister of Health must cause to be tabled in each House of Parliament a report setting out (a) the measures from the national framework that have been implemented and their effectiveness in supporting individuals with sickle cell disease, their families and their caregivers; and (b) with respect to any measure included in the national framework that has not been implemented, the reason it has not been implemented and the timeline for doing so.

Version History

November 19, 2025 at 03:29 PM

Doc ID: 13751454

May 29, 2025 at 06:28 AM

Doc ID: 13540352